CD163+CD14+ macrophages, a potential immune biomarker for malignant pleural effusion
Authors:
- 6 May 2015
- journal article
- research article
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 64 (8) , 965-976
Abstract
Malignant pleural effusion (MPE) is a common complication caused by malignant diseases. However, subjectivity, poor sensitivity, and substantial false-negative rates of cytology assay hamper accurate MPE diagnosis. The aim of this study was to assess whether CD163+CD14+ tumor-associated macrophages (TAMs) could be used as a biomarker for enabling sensitive and specific MPE diagnosis. Pleural effusion samples and peripheral blood samples were collected from 50 MPE patients and 50 non-malignant pleural effusion (NMPE) patients, respectively. Flow cytometry was performed to analyze cell phenotypes, and RT-qPCR was used to detect cytokine expression in these monocytes and macrophages. A blinded validation study (n = 40) was subsequently performed to confirm the significance of CD163+CD14+ TAMs in MPE diagnosis. Student’s t test, rank sum test, and receiver operating characteristic curve analysis were used for statistical analysis. Notably, CD163+CD14+ cell frequency in MPE was remarkably higher than that in NMPE (P < 0.001). In a blinded validation study, a sensitivity of 78.9 % and a specificity of 100 % were obtained with CD163+CD14+ TAMs as a MPE biomarker. In total (n = 140), by using a cutoff level of 3.65 %, CD163+CD14+ cells had a sensitivity of 81.2 % and a specificity of 100 % for MPE diagnosis. Notably, MPE diagnosis by estimating CD163+CD14+ cells in pleural effusion could be obtained one week earlier than that obtained by cytological examination. CD163+CD14+ macrophages could be potentially used as an immune diagnostic marker for MPE and has better assay sensitivity than that of cytological analysis.Keywords
This publication has 43 references indexed in Scilit:
- Diagnostic and prognostic significance of survivin levels in malignant pleural effusionRespiratory Medicine, 2013
- The Inflammatory Microenvironment in Hepatocellular Carcinoma: A Pivotal Role for Tumor-Associated MacrophagesBioMed Research International, 2012
- The Distribution of Macrophages with a M1 or M2 Phenotype in Relation to Prognosis and the Molecular Characteristics of Colorectal CancerPLOS ONE, 2012
- Pleural fluid cell-free DNA integrity index to identify cytologically negative malignant pleural effusions including mesotheliomasBMC Cancer, 2012
- Differential macrophage programming in the tumor microenvironmentTrends in Immunology, 2012
- Macrophages in malignant pleural effusions – alternatively activated tumor associated macrophagesContemporary Oncology, 2012
- Tumour macrophages as potential targets of bisphosphonatesJournal of Translational Medicine, 2011
- The M1 form of tumor-associated macrophages in non-small cell lung cancer is positively associated with survival timeBMC Cancer, 2010
- The Malignant Pleural Effusion as a Model to Investigate Intratumoral Heterogeneity in Lung CancerPLOS ONE, 2009
- “Re-educating” tumor-associated macrophages by targeting NF-κBJournal of Experimental Medicine, 2008